121 related articles for article (PubMed ID: 26144903)
1. Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with β-thalassemia major.
Papadatou I; Orthopoulos G; Theodoridou M; Spoulou V
Vaccine; 2015 Jul; 33(32):3779-83. PubMed ID: 26144903
[TBL] [Abstract][Full Text] [Related]
2. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
Papadatou I; Lagousi T; Kattamis A; Spoulou V
Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
[TBL] [Abstract][Full Text] [Related]
3. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
Papadatou I; Piperi C; Alexandraki K; Kattamis A; Theodoridou M; Spoulou V
Clin Infect Dis; 2014 Sep; 59(6):862-5. PubMed ID: 24879786
[TBL] [Abstract][Full Text] [Related]
5. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals.
Nived P; Jørgensen CS; Settergren B
Vaccine; 2015 Mar; 33(14):1688-94. PubMed ID: 25707692
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
7. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia.
Orthopoulos GV; Theodoridou MC; Ladis VA; Tsousis DK; Spoulou VI
Vaccine; 2009 Jan; 27(3):350-4. PubMed ID: 19010369
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
[TBL] [Abstract][Full Text] [Related]
9. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
11. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Klein NP; Ensor K; Jouve S; Northington R; Moscariello M; McGovern PC
Pediatr Infect Dis J; 2013 Sep; 32(9):990-7. PubMed ID: 24008739
[TBL] [Abstract][Full Text] [Related]
12. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
13. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
14. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
[TBL] [Abstract][Full Text] [Related]
16. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients.
Meerveld-Eggink A; de Weerdt O; van Velzen-Blad H; Biesma DH; Rijkers GT
Vaccine; 2011 Jan; 29(4):675-80. PubMed ID: 21115060
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
[TBL] [Abstract][Full Text] [Related]
20. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults.
Lazarus R; Clutterbuck E; Yu LM; Bowman J; Bateman EA; Diggle L; Angus B; Peto TE; Beverley PC; Mant D; Pollard AJ
Clin Infect Dis; 2011 Mar; 52(6):736-42. PubMed ID: 21367726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
